Fig. 5

S6 inhibits the growth of breast cancer cells and tumors. A CCK8 assay analysis of half-maximal inhibitory concentration (IC₅₀) of S6 for SCP2 cells (1.89 µM, 95%CI 1.27–2.74). B The effect of S6 (2 µM), DMSO, EADM (50 µM), and DTX (5 nM) on the viability of SCP2 cells. C Inhibition of S6 on the growth of breast-cancer organoids and the inhibition rates of treatment with 80 μM S6 for 48 h (38.96%, 95%CI 37.01 to 40.89), compared to that of 2 μM S6 for 48 h (0.53%, 95%CI 0.12 to 0.92), as well as EADM (500 µM) and DTX (250 nM). D Survival of SCP2 tumor-bearing mice after treatment with S6 or DMSO (n = 8–10 per group, P = 0.0063). E Body weights of SCP2 tumor-bearing mice after treatment with DMSO or S6 (10 mg/kg) for 45 days (P = 0.0081). F Western blot analysis of the relative levels of SOST, KRAS, TGF-β, SMAD3, CXCR4, and STAT3 expression and STAT3 phosphorylation in SCP2 cells after treatment with DMSO or S6 (2 µM) for 48 h